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Abstract
Background: An interaction between lectins from marine algae and PLA2 from rattlesnake was
suggested some years ago. We, herein, studied the effects elicited by a small isolectin (BTL-2),
isolated from Bryothamnion triquetrum, on the pharmacological and biological activities of a PLA2
isolated from rattlesnake venom (Crotalus durissus cascavella), to better understand the enzymatic
and pharmacological mechanisms of the PLA2 and its complex.
Results: This PLA2 consisted of 122 amino acids (approximate molecular mass of 14 kDa), its pI
was estimated to be 8.3, and its amino acid sequence shared a high degree of similarity with that of
other neurotoxic and enzymatically-active PLA2s. BTL-2 had a molecular mass estimated in
approximately 9 kDa and was characterized as a basic protein. In addition, BTL-2 did not exhibit
any enzymatic activity.
The PLA2 and BTL-2 formed a stable heterodimer with a molecular mass of approximately 24–26
kDa, estimated by molecular exclusion HPLC. In the presence of BTL-2, we observed a significant
increase in PLA2 activity, 23% higher than that of PLA2 alone. BTL-2 demonstrated an inhibition of
98% in the growth of the Gram-positive bacterial strain, Clavibacter michiganensis michiganensis
(Cmm), but only 9.8% inhibition of the Gram-negative bacterial strain, Xanthomonas axonopodis pv
passiflorae  (Xap). PLA2 decreased bacterial growth by 27.3% and 98.5% for Xap and Cmm,
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respectively, while incubating these two proteins with PLA2-BTL-2 inhibited their growths by 36.2%
for Xap and 98.5% for Cmm.
PLA2 significantly induced platelet aggregation in washed platelets, whereas BTL-2 did not induce
significant platelet aggregation in any assay. However, BTL-2 significantly inhibited platelet
aggregation induced by PLA2. In addition, PLA2 exhibited strong oedematogenic activity, which was
decreased in the presence of BTL-2. BTL-2 alone did not induce oedema and did not decrease or
abolish the oedema induced by the 48/80 compound.
Conclusion: The unexpected results observed for the PLA2-BTL-2 complex strongly suggest that
the pharmacological activity of this PLA2 is not solely dependent on the presence of enzymatic
activity, and that other pharmacological regions may also be involved. In addition, we describe for
the first time an interaction between two different molecules, which form a stable complex with
significant changes in their original biological action. This opens new possibilities for understanding
the function and action of crude venom, an extremely complex mixture of different molecules.
Background
Lectins are carbohydrate-binding proteins of non-
immune origin found in a wide variety of living organ-
isms that decipher glycocodes in the structure of glycans
attached to soluble and integral cell membrane glycocon-
jugates [1]. Mechanisms for sugar recognition in microor-
ganisms, plants, and animals are independently involved
in several protein frameworks [2]. Protein-carbohydrate
interactions play biological roles in many cellular proc-
esses, such as cell communication, host defence, fertiliza-
tion, development, parasitic infection and tumour
metastasis. Although, in many instances, their exact bio-
logical roles remain unknown, many lectins have been
extensively studied as biochemical tools in biotechnology
and biomedical research. Marine algal lectins, however,
have been described at a low pace, since the first report on
their haemagglutinating activity 40 years ago [3]. Marine
organisms are recognized as rich sources of diverse and
biologically-active molecules, many lectins from red and
green marine algae have been isolated and characterised
to date from more than 40 species. Amongst activities of
potential therapeutic and diagnostic interest are the inhi-
bition of fungal growth [4], induction and inhibition of
human lymphocyte transformation [5], identification of
methacillin-resistant Streptococcus aureus [6], induction of
mitogenic activity [7], antibiotic activity against marine
vibrios [8], endothelium-dependent relaxation of the rat
aorta [9], inhibition of platelet aggregation [10], and as an
anti-HIV protein [11].
In each family of lectins, the structure of their carbohy-
drate recognition domains (CRDs) is essentially con-
served. Similar domains have been found in some
phospholipase A2 (PLA2) receptors named M and N-type
and play an important role in the pharmacological activ-
ity of PLA2 [12]. Phospholipases A2 (PLA2) (EC 3.1.1.4)
from snake venom are very small proteins that catalyse the
hydrolysis of glycerophospholipids at the sn-2 position in
a Ca+2-dependent reaction, releasing lysophospholipids
and fatty acids [13]. Snake PLA2s have many pharmaco-
logical effects, such as: neurotoxicity, myotoxicity, haemo-
lytic activity, haemorrhagic and oedematogenic activities
[13,14]. PLA2s that have lysine at the position 49 (Lys 49
or K49) [15] structurally keep the same motifs of PLA2s
that have aspartate at the position 49 (Asp 49 or D49, cat-
alytically active), but their enzymatic activity is lost.
Despite this, these proteins display many biological activ-
ities, regardless of arachidonic acid release [16-18].
In 2000, Hori et al [19] developed the haemagglutinating
activity assay, combining algal lectins (hypnin A) and
PLA2s from the snakes, Naja naja and Crotalus adamanteus,
and found an interaction between proteins, demonstrated
by the inhibition of haemagglutination at a relatively low
concentration [19]; it was suggested that this effect proba-
bly was dependent on a protein-recognition site present in
the lectin surface where the PLA2 would bind. Thus, some
algae lectin-like proteins may play other important bio-
logical functions, such as providing an alternative source
of a novel class of PLA2 inhibitors. In this article, we inves-
tigate the effects induced by a new isolectin from the red
marine alga, Bryothamnion triquetrum, on some of the bio-
logical activities of PLA2 and the interaction with catalyti-
cally-active PLA2 from snake venom.
Results
After the first purification step, on a preparative DEAE col-
umn, the main fraction, named Bryothamnion triquetrum
lectin (BTL), was obtained and then dialyzed and
lyophilised. The chromatography of BTL showed the pres-
ence of two main fractions, further named BTL-1 and BTL-
2, which is the most abundant isoform isolated (Fig. 1a).
After Reverse Phase HPLC, lectins were obtained with a
high degree of purity (Fig. 1b). SDS-PAGE of BTL-2
revealed the presence of one main protein band with an
estimated molecular mass of 9.0 kDa (Fig. 1c). The N-ter-BMC Biochemistry 2008, 9:16 http://www.biomedcentral.com/1471-2091/9/16
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minal sequences of both lectins were deduced and
showed a high homology with BTL [20] and hypnins [19]
(Fig. 2a). In addition, BTL-1 and BTL-2 had a pI of around
8.6. Circular dichroism spectra of BTL-2 were obtained in
the wavelength region of 190 – 250 nm, revealing mostly
random coil structures and a low content of α-helices or
β-sheets (Fig. 2b).
PLA2  was purified to high molecular homogeneity by
reverse phase HPLC (Figure 3a), which resulted in only
one electrophoretic band (Figure 3b). The estimated pl
value of this purified protein was 8.3 (Figure 3c). Molecu-
lar exclusion chromatography indicated a molecular mass
of approximately 10.0 kDa for the isolated BTL-2; 15.0
kDa for the isolated PLA2, while the PLA2 and BTL-2, when
incubated for 30 minutes, had a single peak with a molec-
ular mass of approximately 24.0 – 26.0 kDa (Figure 3d).
The PLA2  was characterized as an enzymatically-active
D49 PLA2 with moderate enzymatic activity in compari-
son with PLA2 from Naja naja. In the presence of BTL-2, we
observed a significant increase of 23% in the enzymatic
activity of PLA2, when compared with the PLA2 alone (Fig-
ure 4a).
BTL-2 demonstrated an inhibition of 98% in the growth
of the Gram-positive bacterial strain, Clavibacter michigan-
ensis subsp. michiganensis (Cmm), but only a 9.8% inhibi-
tion of the Gram-negative bacterial strain, Xanthomonas
axonopodis pv passiflorae (Xap). PLA2 decreased Xap bacte-
rial growth by 28.3% and Cmm growth by 98.5%, whilst
incubation of these two proteins PLA2-BTL-2 inhibited 
2a) BTL-1 and BTL-2 were previously reduced and car- boxymethylated and later sequenced in an automatic gas-liq- uid sequencer Procise f (Applied Biosytem) Figure 2
2a) BTL-1 and BTL-2 were previously reduced and 
carboxymethylated and later sequenced in an auto-
matic gas-liquid sequencer Procise f (Applied Bio-
sytem). 2b) The CD spectra were obtained using a J715 
spectropolarimeter (Jarco Cop., Japan). BTL-2 was dissolved 
in water and the solution was adjusted to a final concentra-
tion of 10 mM of protein.
1a) HPLC profile of BTL-2 using an ion exchange column,  protein Pack SP 5PW (Waters) Figure 1
1a) HPLC profile of BTL-2 using an ion exchange column, protein Pack SP 
5PW (Waters). Approximately 5 mg of the sample, obtained from the DEAE col-
umn, were dissolved in 0.05 M ammonium bicarbonate and applied onto the chroma-
tographic column. The chromatography showed the presence of two main fractions 
containing haemagglutinating activity, named BTL-1 and BTL-2. The run was moni-
tored at 280 nm and the elution was conducted using a discontinuous linear gradient 
of ammonium bicarbonate at a concentration of 1.0 M, pH 8.0, constant flow rate of 
1 mL/min. 1b) The BTL-2 fraction was subjected to a final chromatography in a 
Reverse phase HPLC fractionation using a μ-Bondapack C18 column. The elution of 
samples was carried out using a linear gradient concentration of an aqueous solution 
of 66% acetonitrile and was monitored at 280 nm at a constant flow rate of 1 mL/min. 
Samples were previously dissolved in buffer A (0.1% TFA) that was used to equili-
brate the column. 1c) Following the method [43], a discontinuous electrophoresis 
was performed with a final acrylamide concentration of 12% in the running gel. All 
the samples and the molecular markers were treated with SDS and DTT 1 M and the 
run was conducted at 40 mA. The samples were stained with Coomassie brilliant 
blue R-250. The SDS-PAGE profile of BTL-2 showed high molecular homogeneity in a 
single band with estimated molecular mass of approximately 9.0 kDa.BMC Biochemistry 2008, 9:16 http://www.biomedcentral.com/1471-2091/9/16
Page 4 of 12
(page number not for citation purposes)
4a) The enzymatic activity assay [45] was analyzed using an  Elisa plate containing 200 μL of buffer (10 mM Tris-HCl, 10  mM CaCl2, 100 mM NaCl, pH 8.0), 20 μL of substrate (3  mM, 4-nitro-3-octanoyloxy-bencoic acid), 20 μL of water and  20 μL of the sample at a concentration 1 μg/μL or 2 μg/μL  when both proteins were incubated together Figure 4
4a) The enzymatic activity assay [45] was analyzed using an Elisa plate 
containing 200 μL of buffer (10 mM Tris-HCl, 10 mM CaCl2, 100 mM NaCl, 
pH 8.0), 20 μL of substrate (3 mM, 4-nitro-3-octanoyloxy-bencoic acid), 20 
μL of water and 20 μL of the sample at a concentration 1 μg/μL or 2 μg/μL 
when both proteins were incubated together. After 20 minutes from the 
beginning of the reaction, the absorbance was measured at 425 nm using a Spec-
traMax 340 multiwell plate reader (Molecular Devices). It is possible to observe that 
the enzymatic activity of the PLA2 was increased in the presence of BTL-2. 4b) and 
4c) Clavibacter michiganensis subsp. michiganensis and Xanthomonas axonopodis pv.passi-
florae were harvested from fresh agar plates and suspended in distilled and sterilized 
water (A600 nm = absorbance). BTL-2 demonstrated an inhibition of 98% of the 
growth of the Gram-positive bacterial strain, Clavibacter michiganensis subsp. michigan-
ensis (Cmm), but only a 9.8% inhibition of the Gram-negative bacterial strain, Xan-
thomonas axonopodis pv passiflorae (Xap). PLA2 decreased Xap bacterial growth by 
28.3% and Cmm growth by 98.5%, whilst incubation of these two proteins PLA2-BTL-
2 inhibited their growths by 36.2% for Xap and 98.5% for Cmm.
3a) The venom from the Crotalus durissus cascavella rattle- snake was fractionated by HPLC molecular exclusion chro- matography (Superdex 75 column 1 × 60 Cmm) and the  active fraction was subjected to Reverse Phase HPLC (μ- Bondapack C18 column) to obtain a high purity protein Figure 3
3a) The venom from the Crotalus durissus cascavella rattlesnake was frac-
tionated by HPLC molecular exclusion chromatography (Superdex 75 col-
umn 1 × 60 Cmm) and the active fraction was subjected to Reverse Phase 
HPLC (μ-Bondapack C18 column) to obtain a high purity protein. 3b) Fol-
lowing the Laemmli method [43], a discontinuous electrophoresis was performed 
with a final acrylamide concentration of 12% in the running gel. All the samples and 
the molecular markers were treated with SDS and 1 M DTT and the run was con-
ducted at 40 mA. The samples were stained with Coomassie brilliant blue R-250. The 
SDS-PAGE profile of PLA2 showed high molecular homogeneity in a single band with 
an estimated molecular mass of approximately 14.0 kDa. 3c) Two dimensional elec-
trophoresis showing one protein spot with molecular mass of around 14 kDa and pI 
of approximately 8.3. 3d) One milligram of sample was dissolved in 0.5 mL of 0.05 M 
phosphate buffer, pH 7.5, and applied to a Protein Pack TSK gel 3000 column (0.8 
Cmm 30 Cmm) equilibrated with this same buffer. This procedure was performed 
with one milligram of each protein, incubated together and with all molecular mass 
markers to estimate the molecular weight of the samples. It is possible to observe a 
peak with an estimated molecular mass of 10 kDa from BTL-2, another with 15 kDa 
from PLA2 and another of approximately 24–26 kDa that corresponds to both incu-
bated proteins.BMC Biochemistry 2008, 9:16 http://www.biomedcentral.com/1471-2091/9/16
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their growths by 36.2% for Xap and 98.5% for Cmm (Fig-
ures 4b and 4c).
The PLA2 isolated from Crotalus durissus cascavella showed
a strong platelet aggregation activity in washed platelets
(Figures 5 and 6). The aggregation induced by PLA2 was
very effective (Figure 5b), while BTL-2, at same concentra-
tion, did not produce any effect (Figure 5a). When PLA2
was incubated with BTL-2, we observed a significant
decrease in the effect of PLA2 on platelet aggregation in the
concentrations of 1 μg and 3 μg, respectivaly, 72.7% and
48.8%, when compared to PLA2 alone (Figure 5c). The
averaged platelet aggregation assay data is depicted in Fig-
ure 6.
BTL-2, injected in the paw of rats, did not induce an evi-
dent inflammation and its oedematogenic effect was sim-
ilar to that of the saline control (Figure 7a). PLA2 from C.
durissus cascavella venom induced a strong oedema
response at 15 minutes following injection. The maxi-
mum inflammatory response was observed at 30 min fol-
lowing injection of PLA2. Under the same experimental
conditions, PLA2 incubated with BTL-2, exhibited a lower
oedematogenic effect, compared to non-incubated PLA2
(Figure 7a). In addition, BTL-2 did not inhibit the oedema
induced by compound 48/80 (C48/80), a potent oedema-
togenic agent that induces the release of inflammatory
mediators (Figure 7b).
PLA2 from Crotalus durissus cascavella shared a high degree
of amino acid similarity with other rattlesnake venom
PLA2s, such as the PLA2s isolated from Crotalus durissus ter-
rificus isoforms 15, 16 and 17 (Cdt F15, F16 and F17),
CROTOX B and MOJAVE B (Figure 8). Furthermore, the
amino acid sequence of PLA2 was highly conserved at the
N-terminal region, calcium-binding region, active site, α-
helical and β-wing. Based on its three dimensional struc-
ture,  Crotalus durissus cascavella PLA2  exhibited a high
number of random coil structures, mainly in the calcium
binding and the C-terminal loops (Figure 9a and 9b). The
3D model also suggests the presence of an extensive loop
that connects helix 1 to helix 2 and other significantly
long random coil structures on the C-terminal region (Fig-
ure 9a) in this PLA2.
Discussion and Conclusion
The interaction between a marine alga lectin and a PLA2
from a rattlesnake was first detected by Hori et al 2000
[19]. Herein, we report the marine alga extract purifica-
tion of BTL-2, one of the lectin isoforms isolated from the
red marine alga Bryothamnion triquetrum. Lectins from B.
triquetrum, with low molecular weight, share similar struc-
tural features with other low molecular weight lectins iso-
lated from red algae, such as Hypnea japonica [19]. These
structural similarities found suggest the importance of this
The washed platelets assay was performed with venous  blood collected from healthy volunteers Figure 5
The washed platelets assay was performed with 
venous blood collected from healthy volunteers. The 
blood was centrifuged in 3.8% trisodium-citrate for 10 min-
utes at 200 × g and the residue was centrifuged again for 20 
minutes at 1500 × g. Aggregations were performed in 1 μg 
and 3 μg concentrations in 20 μL of BTL-2, PLA2 and the two 
proteins (v/v). 5a) BTL-2 induced low aggregation, however 
the PLA2 induced high aggregation at these concentrations, 
and both proteins induced a lower aggregation when com-
pared with the PLA2 alone.BMC Biochemistry 2008, 9:16 http://www.biomedcentral.com/1471-2091/9/16
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protein for the development of these organisms and
define a low molecular weight class of lectin.
Hori et al (2000) [19] suggested that the interaction
between marine alga lectin and PLA2 was correlated to the
presence of a specific interaction domain. Experiments
conducted by these authors showed that the haemaggluti-
nation activity of hypnins was strongly inhibited by the
addition of PLA2, which strongly suggests that the interac-
tion between hypnins and PLA2 involves specific molecu-
lar recognition. Accordingly [19], hypnins have two
distinct binding sites; a carbohydrate-recognition site(s)
(probably containing a C-type CRD motif) and a protein-
recognition site(s) (phospholipase A2-binding site). Inter-
estingly, the interaction between PLA2 with hypnins did
not affect the hemolytic activity induced by PLA2.
The N-terminal amino acid sequence of BTL-2 has a high
homology with the lectins of Hypnea japonica, which prob-
ably possess the C-type CDR motif [19], as such BTL-2
probably possesses these same sites in its structure. The
CD spectra analysis revealed that both BTL-2 and BTL-1
have a predominance of random coils, stabilized by
disulfide bridges, conferring some interesting properties
to these proteins such as resistance to high temperatures,
very similar to hypnins which possess thermostability
[19].
The catalysis of enzymatically-active PLA2 can be affected
by factors such as substrate, and PLA2 activity is strongly
enhanced by aggregated substrates that include micelles
or monolayers [21]. Another important factor is substrate
concentration, when the Critical Micelle Concentration
(CMC) is reached, this enhances the enzymatic activity by
several orders of magnitude [22,23]. Conformational
Male Wistar rats (120 g–150 g) were anaesthetised with  halothane (inhaled) Figure 7
Male Wistar rats (120 g–150 g) were anaesthetised 
with halothane (inhaled). The paw oedema was induced 
by a single subplantar injection of 100 μL of sample 100 μg/
paw). Paw volume was measured immediately before the 
injection and the intervals thereafter (15, 30, 60 and 120 min-
utes) using a hydroplethysmometer (model 7150, Ugo Basile, 
Italy). 7a) BTL-2 induced similar oedema simihat of the saline 
control. PLA2 showed the highest oedema at 30 minutes 
before the injection. The presence of BTL-2 decreased the 
oedema induced by the enzyme. 7b) The compound 48/80 
(C48/80) was used, incubated with BTL-2, to show that the 
lectin was not acting on the tissues to decrease the action of 
PLA2, but was probably binding to the enzyme. Thus, the lec-
tin did not decrease the action of C48/80 act.
6a) For the concentrations 1 μg and 3 μg, the PLA2 induced  high aggregations Figure 6
6a) For the concentrations 1 μg and 3 μg, the PLA2 
induced high aggregations. When PLA2 was incubated for 
30 minutes with BTL-2 at the same concentrations of 1 μg/1 
μg and 3 μg/3 μg (v/v) in 20 μL volume it was possible to 
observe that the PLA2 induced a lower aggregation when 
compared to the PLA2 alone (n = 5; p < 0.05).BMC Biochemistry 2008, 9:16 http://www.biomedcentral.com/1471-2091/9/16
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changes in the structure of PLA2 are also an important fac-
tors that increase enzymatic activity [24]; these changes
are located in the N-terminal residue and in the surface
binding loop in which the calcium binding loop is
located. The main conformation change, located in the N-
terminal helix, has a small shift towards the calcium ion
of PLA2. The role and structural relevance of the N-termi-
nal region have also been reported [25-27]. In addition,
the suppression or the chemical modification of the N-ter-
minal region results in a strong reduction in the enzymatic
activity of catalytically-active PLA2.
It has been reported that highly-purified heparin sodium
salt is able to increase the enzymatic activity of catalyti-
cally-isolated PLA2 from Crotalus durissus terrificus venom
[28,29]. The potentialization of the enzymatic activity of
heparin has been observed in the treatment of some vas-
cular disorders in clinical trials. On the other hand, the
inhibitory effects of the neurotoxic or other pharmacolog-
ical activities of PLA2 are well known. The mechanism of
action of PLA2 towards heparin involves inducible confor-
mation changes to the active site, the N-terminal region,
and strong binding with the cationic site located in the C-
terminal region [30-32], which leads to the modifications
Amino acid sequence of PLA2 isolated from Crotalus durissus cascavella and its estimated secondary structure Figure 8
Amino acid sequence of PLA2 isolated from Crotalus durissus cascavella and its estimated secondary structure. 
The calcium binding loop, active site and C-terminal region are present in the sequence. Note the highly conserved calcium 
binding loop and active site, and an extensive portion of basic amino acid residues, such as Arg and Lys, in the C-terminal. This 
PLA2 showed high homology with other PLA2s, such as the isoforms from Crotalus durissus terrificus (Cdt F15, F16 and F17). 
Crotoxin B (cloned basic subunit of crotoxin) and mojave b (PLA2 subunit of Crotalus scutulatus scutulatus).BMC Biochemistry 2008, 9:16 http://www.biomedcentral.com/1471-2091/9/16
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in the biological effects induced by the catalytically-active
PLA2.
Our results showed that this novel basic hypnin-like lec-
tin, isolated from Bryothamnion triquetrum, seems to form
a heterodimeric structure with PLA2 from the Crotalus
durissus cascavella venom and that its molecular binding
strongly increases the enzymatic activity of PLA2. Further-
more, our data suggest that the complex that is established
between PLA2, from Crotalus durissus cascavella, and lectin,
from Bryothamnion triquetrum, probably involves a hydro-
phobic contact and indirectly affects the catalytic site of
PLA2. Thus, our results show that some pharmacological
activities, induced by PLA2 isolated from Crotalus durissus
cascavella, did not involve its solely enzymatic activity,
indicating that the specific actions induced by this PLA2
are due to the presence of pharmacological sites on the
protein surface, which are distinct from catalytic sites,
allowing PLA2 to bind specifically to soluble proteins or
membrane-bound proteins that participate in the mecha-
nism of action and this is not an isolated case, as observed
for other PLA2 from other sources [33,34]. The antibacte-
rial activity, however, is very dependent on the ability of
this PLA2 to destroy the bacterial membrane. These facts
are supported by the results of the bacterial growth rate of
Xap, which was strongly inhibited by a complex formed
by PLA2 and BTL-2.
Conversely, the platelet aggregation assay showed that the
presence of the lectin significantly decreased the PLA2
aggregation effect, showing that the pharmacological
activity of the enzyme was affected by BTL-2. This same
effect occurred in the oedema assay, where in the presence
of the lectin, the pharmacological activity of the PLA2 was
decreased, inducing a lower oedema. The hydrolysis of
arachidonic acid (AA) by the PLA2 generates free AA and
lysophospholipids that are the precursors of eicosanoids
and platelet-activating factor, respectively [35]. At first, it
was thought that secretory PLA2s served to provide sub-
strates for the biosynthesis of proinflammatory lipid
mediators; however, it was found that not all PLA2 hydro-
lyze AA from intact mammalian cells, suggesting that the
generation of lipid mediators is not a general function of
this enzyme [36,37]. A great breakthrough was the identi-
fication of other biological effects of PLA2 in cells involved
in inflammatory and immune responses. As such, these
results support the idea of the presence of another phar-
macological site in the PLA2, isolated from the Crotalus
durissus terrificus, which is distinct from the enzymatic site.
Something similar is observed in some other PLA2 that
interact with target cells via membrane peptidoglycans
and with specific or promiscuous receptors [11] and, in
some cases, lead to activation of some intracellular cyto-
plasmic PLA2 and several proteins including PKA and PKC
[37-39]. Some specific mutation studies carried out with
PLA2 showed that the binding of secretory PLA2 to the
receptor involves a specific recognition of the CRD region
of this receptor [34,36,37], which is located near the cata-
lytic site of PLA2. Our results, however, suggest that the
PLA2 region involved in the binding with BTL-2 produces
a structural change that results in the reduction of its phar-
macological action, compared to untreated PLA2. The
C48/80 experiment supports this argument, since it shows
that the lectin was not binding to the tissues to hinder the
C48/80 or PLA2 activity, but that it was acting in the PLA2.
The three dimensional model of PLA2 from Crotalus durissus  cascavella venom was determined by comparative homology  modelling using BLASTP in Protein Data Bank Figure 9
The three dimensional model of PLA2 from Crotalus 
durissus cascavella venom was determined by com-
parative homology modelling using BLASTP in Pro-
tein Data Bank. The model shows the β-wing, α-helix, 
calcium binding loop, and C-terminal loop.BMC Biochemistry 2008, 9:16 http://www.biomedcentral.com/1471-2091/9/16
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Class I and II secretory PLA2s possess an antiparallel,
poorly conserved β-wing. The structural conformation,
though variable in relation to the rest of the enzyme, is
internally consistent across species. The wing extends out-
wards into the solvent, and the 'wingtip' is poorly
anchored. It has been suggested that biological properties
such as neurotoxicity, myotoxicity or anticoagulation may
be associated with the β-wing [40-42]. The presence of a
similar β-wing motif in the 3D model of the PLA2, isolated
from Crotalus durissus cascavella venom, may explain its
remaining pharmacological activity, which probably has
two distinct pharmacological sites, one located in the ran-
dom coil that links the N-terminal helix with the helix 2
and the β-wing.
The main conclusions of this study are that; 1) the phar-
macological activity of PLA2 from Crotalus durissus cascav-
ella is completely dissociated from its enzymatic activity
and also some of its biological activity. 2) The PLA2 model
revealed that the presence of an extensive hydrophobic
random coiled region may be involved in the interaction
with BLT-2, forming a random-coil based structure.
Methods
Source of algae
Specimens of the red marine alga Bryothamnion triquetrum
were collected from the Atlantic Coast of Brazil (Pacheco
Beach, Ceará) and kept in plastic bags at -20°C until proc-
essed.
Lectin purification
Algae were thawed, rinsed with distilled water, cleaned of
epiphytes, and ground to a fine powder under liquid
nitrogen. The powder was stirred for 4 hours with 0.02 M
phosphate buffer (pH 7.0), with 0.15 M NaCl, filtered
through nylon tissue, and then centrifuged at 7,000 × g,
for 30 min, at 4°C. The supernatant was acidified and
remained under refrigeration for 4 hours. The precipitated
pigments were removed by centrifugation and the super-
natant (crude extract) was adjusted to pH 7.0, followed by
ammonium sulphate precipitation (0–60%). Precipitated
proteins were recovered by centrifugation, dialyzed in dis-
tilled water and applied onto a DEAE-cellulose column,
equilibrated and eluted with 0.02 M phosphate buffer
(pH 7.6), followed by elution with 1.0 M NaCl solution
in the same buffer, at a flow rate of 30 mL/h. The unab-
sorbed fractions with haemagglutinating activity were
pooled and rechromatographed in the same column.
Active fractions containing lectins were dialyzed and
lyophilised (DEAE fraction).
After that, approximately 5 mg of freeze-dried DEAE-frac-
tion was dissolved in 250 μL of ammonium bicarbonate
buffer (0.05 M; pH 7.9) and homogenised until complete
dissolution, followed by clarification by centrifugation
(4,500 × g for 2 min, at 27°C). The supernatant was recov-
ered and injected onto an ion exchange HPLC column
(Protein Pack SP 5PW, 0.75 × 10 cm, Waters), previously
equilibrated with the same buffer used for dissolving the
fraction. The elution was conducted using a discontinu-
ous linear gradient of ammonium bicarbonate at a con-
centration of 1.0 M, pH 8.0, at constant flow rate of 1 mL/
min.
The chromatography was monitored at 280 nm and the
peaks were collected and the two fractions containing hae-
magglutinanting activity were lyophilised and than sub-
jected to the final chromatographic steps of the Reverse
Phase (RP-HPLC). The elution of samples was carried out
using a linear gradient concentration of an aqueous solu-
tion of 66% acetonitrile. Samples were previously dis-
solved in buffer A of RP-HPLC (0.1% TFA) that was used
to equilibrate the column. The fractions were immediately
concentrated by ultrafiltration (AMICON), followed by
dialysis with 5.0 mM ammonium bicarbonate solution
(pH 7.8), sterilized by microfiltration (0.22 μm) and
stored at 4°C for further use.
Electrophoresis
The electrophoresis was carried out following the Lae-
mmli method [43]. The degree of purity of fractions was
assessed by discontinuous electrophoresis using a final
acrylamide concentration of 12% in the running gels (1.0
M Tris-HCl, pH 8.8) and 5% in the stack gel (0.5 M Tris-
HCl, pH 6.8). The electrophoretic run was carried out
using a BIORAD electrophoretic system for SDS-PAGE. All
samples and the molecular marker were treated with SDS
and 1.0 M DTT and the run was conducted at 40 mA for
both plates. After electrophoresis, samples were stained
with Coomassie brilliant blue R-250.
Circular dichroism
The purified BTL-2 was dissolved in water and the solu-
tion was adjusted to a final concentration of 10 mM of
protein. The sample was transferred to a 1 mm path-
length quartz cuvette. Circular dichroism spectra in the
wavelength range of 185–300 nm were obtained using a
J715 spectropolarimeter (Jasco Corp., Japan) using a
bandwidth of 1 nm and a response time of 1s. Data col-
lection was performed at room temperature with a scan-
ning speed of 100 nm/min; a total of nine scans were
accumulated for the sample.
PLA2 purification
PLA2 from the rattlesnake, Crotalus durissussus casvella, was
purified by a combination of chromatographic proce-
dures and its molecular homogeneity was determined by
SDS-PAGE. The whole venom was fractionated by HPLC
molecular exclusion chromatography using a Superdex 75
column (1 × 60 cm). The active PLA2 fraction was thenBMC Biochemistry 2008, 9:16 http://www.biomedcentral.com/1471-2091/9/16
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subjected to Reverse Phase HPLC in a C18 μ-Bondapack
column (0.78 cm × 30 cm) (Waters 991-PDA system). The
column was eluted with a linear gradient (0–66.5%, v/v)
of acetonitrile (solvent B) at a flow rate of 2 mL/min, and
absorbance was monitored at 280 nm. The fractions were
collected manually, lyophilized and stored at -20°C.
Amino acid sequence
Three milligrams of purified protein were dissolved in 200
μl of 6 M guanidine chloride (Merck, Darmstadt, Ger-
many) containing 0.4 mM Tris-HCl and 2 mM EDTA
(final pH 8.15). Nitrogen was flushed over the top of the
protein solution for 15 min, which was then reduced with
DTT (6 M, 200 μl) and carboxymethylated with 14C-
iodoacetic acid and cold iodoacetic acid. Nitrogen was
again flushed over the surface of the solution and the reac-
tion tube sealed. This solution was incubated in the dark
at 37°C for 1 h and desalting was performed on a Sepha-
dex G 25 column (0.7 × 12 cm) in 1 mM acetic acid buffer.
The eluted reduced and carboxymethylated (RC) protein
was lyophilised and stored at -20°C. The RC lectins were
then purified and the N-terminal region sequenced.
For the RC-PLA2, we determined the complete amino acid
sequence of the protein by sequencing the N-terminal
region and the peptides from enzyme-treated PLA2. One
sample of RC-protein was digested with Staphylococcus
aureus protease V8 for 16 hours at 37°C, using an enzyme
-substrate ratio of 1:30. The reaction was stopped by
lyophilisation. A second sample of RC-PLA2 was digested
with Clostripain for 8 hours at 37°C and then lyophilised
[44]; the products were separated by Reverse Phase HPLC
using a Waters PDA 991 system with a C-18 μ-Bondapack
column.
Peptide peaks were isolated using a linear gradient (0–
100% of acetonitrile in 0.1% TFA (V/V)). A third sample
(2 mg) was cleaved with a 15-fold molar excess of cyano-
gens bromide (CNBr) over methionine residues in 70%
formic acid (4 ml) under nitrogen for 24 hours at room
temperature. The reaction mixture was then diluted with
40 mL of water and lyophilised. Excess reagents were
removed by gel filtration on a Sephadex G-25 column (1
× 20 cm) equilibrated with 10% acetic acid. The CNBr
peptide fragments were separated by Reverse Phase HPLC,
using an analytical μ-Bondapack C18 column (0.39 × 30
cm; Waters) with 0.1% TFA as solvent A and acetonitrile
containing 30% of solvent A (solvent B). The elution pro-
file was monitored at 214 nm. Analysis of the amino acid
sequence of the RC-protein, as well as that of the enzymat-
ically-digested fragments were performed with an Applied
Biosystems model Procise f gas-liquid protein sequencer.
The phenylthiohydantoin (PTH) derivatives of the amino
acids were identified with an Applied Biosystems model
450 microgradient PTH-analyser.
PLA2 activity
PLA2 activity was measured [45]. The standard assay mix-
ture contained 200 μL of buffer (10 mM Tris-HCl, 10 mM
CaCl2, 100 mM NaCl, pH 8.0), 20 μL of 2.98 mM sub-
strate (4-nitro-3-octanoyloxy-benzoic acid; 4N3OBA), 20
μL of water, and 20 μL of PLA2 (1 mg/mL) in a final vol-
ume of 260 μL. After the addition of PLA2, the mixture was
incubated for 20 min at 37°C. The increase in absorbance
at 425 nm, due to product formation, was monitored dur-
ing this period and the activity was expressed as nmols of
product formed nmols/min/mg. The inhibitory effect of
BTL-2 (1 mg/mL) on PLA2 activity was investigated by
incubating the two proteins at 37°C for 30 min prior to
assaying the enzyme activity using the SpectraMax 340
multiwell plate reader (Molecular Devices).
HPLC molecular exclusion chromatography of BTL-2 
andBTL-2-PLA2
One milligram of PLA2 from C. d. cascavella was dissolved
in 0.5 mL of 0.05 M phosphate buffer, pH 7.5, and
applied to a Protein-Pack TSK gel 3000 column (0.8 cm ×
30 cm), previously equilibrated with the same buffer
before use. BTL-2 and PLA2  (1:1) were preincubated
together for 30 minutes in phosphate buffer. Separately,
molecular mass markers (bovine serum albumin, 66 kDa;
egg album, 45 kDa; carbonic anhydrase, 29 kDa, and lys-
ozyme 14 kDa) were used to estimate the molecular
weight of PLA2, BTL-2 and PLA2:BTL-2. All molecular
weight markers were dissolved in phosphate buffer at a
concentration of 2 mg/mL. The proteins were eluted at a
flow rate of 0.2 mL/min and the absorbance profile was
monitored at 214 nm.
Platelet aggregation studies
Sample collection and aggregation studies
Venous blood was collected with informed consent from
healthy volunteers who denied taking any medication in
the previous 14 days. Blood was collected by a two-syringe
technique using polypropylene syringes and 19-gauge
needles, and immediately transferred into polypropylene
tubes containing 1/10 of final volume of 3.8% trisodium
citrate.
After removing the platelet-rich plasma (PRP), the
remaining blood was prepared by centrifugation of cit-
rated blood at 200 × g for 10 min and washed platelets
(WP) were obtained from the residue by centrifugation of
citrated blood at 1500 × g for 20 min. The platelets were
left for 1 h at room temperature to recover their sensitivity
to aggregating agents. Platelet counts were performed on
a Coulter S Plus (Coulter Electronics, Hialeah, FL) or by
phase-contrast microscopy. Platelet aggregation was car-
ried out using 400 μL of the washed platelets solution in
a cuvette and kept at 37°C with constant stirring.BMC Biochemistry 2008, 9:16 http://www.biomedcentral.com/1471-2091/9/16
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The desired concentration of protein was added 3 minutes
prior to the addition of platelet aggregation inducers
(thrombin for washed platelets). Subsequently, the aggre-
gation was recorded for 5–10 min by using an aggregom-
eter (Payton Scientific Instruments, Inc, Buffalo, NY).
Aggregation experiments were performed in two concen-
trations (1 μg and 3 μg) of BTL-2, PLA2, and PLA2 incu-
bated with BTL-2 (v/v) in a final volume of 20 μL, which
was previously incubated (30 min) at room temperature.
Paw oedema assay
Male Wistar rats (120–150 g) were anaesthetised with
halothane (inhaled). The rat paw oedema was induced by
a single subplantar injection of 100 μL of BTL-2 (10 μg/
paw), PLA2 (10 μg/paw), and PLA2 incubated with BTL-2
(v/v). Paw volume was measured immediately before the
injection of the samples and at selected time intervals
thereafter (15, 30, 60, and 120 minutes) using a hydrop-
lethysmometer (model 7150, Ugo Basile, Italy). The com-
pound 48/80 (C48/80) was incubated with BTL-D2 to
show that the lectin was not acting on the tissues to
decrease the action of the PLA2. All samples were dis-
solved in sterile saline solution (0.9%). Results were
expressed as the increase in paw volume (mL) and calcu-
lated by subtracting the basal volume.
Antibacterial assay
Xanthomonas axonopodis pv.passiflorae  (Xap) and Clavi-
bacter michiganensis subsp. michiganensis (Cmm) were har-
vested from fresh agar plates and suspended in distilled
and sterilized water (A600 nm = absorbance, correspond-
ing to 3 × 108 CFU/mL). Aliquots of this suspension were
diluted to 3 × 103 CFU/mL and incubated with 100 μL of
BTL-2 (1 mg/mL) for 30 min at 37°C. We then deter-
mined the survival on Agar Nutrient (Difco) Plate (n = 5).
Prediction of the three-dimensional structure of PLA2
Amino acid sequence similarity and alignment searches
were carried out to compare the PLA2 isolated from Cro-
talus durissus cascavella venom against the Protein Data
Bank using BLASTP. The 3D structure of PLA2 was deter-
mined by comparative homology modelling. Using com-
puter graphics, the amino acid sequence of PLA2 was fitted
to the high-resolution X-ray structure of the homologous
1BJJ_A. This allowed the construction of a model, which
was then subjected to energy minimization and molecular
dynamic simulations.
Statistical analyses
The results were reported as the means ± SEM of n experi-
ments. The significance of differences between means was
assessed by analysis of variance, followed by a Dunnett's
test when several experimental groups were compared
with the control group. The confidence limit for signifi-
cance was 5% (p > 0.05).
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